Consolidated Financial Result Digest FY2021 Q4 (Fiscal Year Ending March 31, 2021)



April 30, 2021

May 11, 2021 – Partial change in Page 5 and 28



Any information incorporated in this document is not intended for suggestion of purchase or sale of equity share of the company. All the description and projection are based on the company's own analysis at the time of compilation, and their accuracy is not guaranteed. These data may be revised without prior announcement. The company will neither assume nor compensate any loss of anybody resulting from decision based on information provided here.



Our Reporting Segments

Electronics Materials

Develops, manufactures, purchases and sells chemicals for PWBs and other electronic components





Medical and Pharmaceuticals

Develops, manufactures, and sells pharmaceuticals and quasi-drugs





Other

Manufactures and sells dyes, pigments and other chemical products, supplies renewable energy, software development





FY2021 Q4 Overview

Cumulative Sales for fiscal year ending March 2021 increased YoY by 9%, hitting record high profits

Main reason

Electronics Materials Business

- Increase in remote working and online classes led to continued high demand for electronic devices for data centers and PCs
- 4Q results were higher than usual because of continued operation of our customers during the Chinese New Year holidays
- Strengthening our overseas production bases Taiyo Ink Vietnam, Taiwan Taiyo, OTC JiangXi (Start operations from July)

Medical and Pharmaceutical Business

Cumulative Sales for fiscal year ending March 2021 increased YoY by 35% (EBITDA YoY by 101%)

Main reason

- Contribution from Taiyo Pharma Tech set up in October 2019
- Contribution from 4 long-term listed drugs acquired from AstraZeneca in April 2020
- Taiyo Pharmatech acquired a distribution center in Osaka

Other

Acquisition of Treasury Stock

Total number of shares acquired: 256,400

Total acquisition price of shares: Approximately 1,500 million yen



Consolidated Financial Results


Results Summary

	Fiscal year 2020 Full year	Fiscal year 2021 Full year	Fiscal year 2021 Announced on Feb 5, 2021 Full year			
	Result	Result	YoY	%	Earnings Forecast	%
Net Sales	70,627	80,991	10,364	15%	80,500	101%
Operating Income	9,136	13,943	4,807	53%	13,300	105%
Ordinary Income	8,898	13,819	4,921	55%	13,200	105%
Net Income	3,749	9,529	5,780	154%	9,000	106%
Exchange rate of JPY/USD	109.1	106.2	-2.9		105	
EBITDA	14,774	21,420	6,646	45%	20,700	103%
Operating Income Margin	13%	17%			17%	
EBITDA Margin	21%	26%			26%	

Unit: JPY Million

Performance by Segment

Cumulative 4Q Net Sales / Operating income / EBITDA Unit: JPY Million




** Since the third quarter of fiscal year ended March 31st 2020, we include Amortization of Goodwill among the each reportable segment. Also, from the first quarter of this year, some expenses that were previously included in company-wide expenses are allocated to each report segment.

TAIYO HOLDINGS CO., LTD.



Trend of Quarterly Performance



Overview of BS

BS- Comparision with the previous term Unit: JPY Million

	20/3	21/3	Change		20/3	21/3	Change
Cash and Deposits	29,191	54,705	25,514	Short term borrowings × 2	10,893	21,885	10,992
Accounts Receivables	19,513	22,527	3,014	Long term borrowings	44,818	59,333	14,515
Inventory※1	11,408	13,447	2,039	Notes and Account payable	7,231	7,907	676
Others	2,267	2,258	A 9	Others	9,726	13,379	3,653
Total Current Assets	62,380	92,937	30,557	Total Liabilities	72,668	102,504	29,836
Tangible Fixed Assets	44,761	46,348	1,587	Shareholders Equity	69,651	74,184	4,533
Intangible Fixed Assets	30,769	34,949	4,180	Others	▲ 429	1,954	2,383
Others	4,281	4,766	485	Non-controlling interest	301	357	56
Total Fixed Assets	79,811	86,063	6,252	Total net assets	69,523	76,497	6,974
Total Assets	142,192	179,001	36,809	Total liabilities and net assets	142,192	179,001	36,809
		}		Equity to Asset	48.7%	42.5%	-6.2%

Ratio

X1 Inventories: Goods and products + work in process + raw materials and stored good

X2 Short-term borrowings: Short-term borrowings + long-term borrowings scheduled to be repaid within one year



48.7%

42.5%



Acquisition of treasury stock


Treasury stock acquisition status and plan

Total number of 256,400 shares acquired FY2021 **Total acquisition** 1,499,972,992 yen Result price of shares **Acquisition** Feb 1 ∼ March 22, 2021 period As in the previous fiscal year, we have resolved FY2022 an upper limit of 1.5 billion yen

Commemorative Dividend on 20th anniversary of our listing on the First Section of the Tokyo Stock Exchange

In January 2021, we celebrated the 20th anniversary of our listing on the First Section of the Tokyo Stock Exchange. To show our appreciation for the support from the shareholders, we have decided our year-end dividend forecast for the fiscal year ending March 2021 to be a total of 95.10 yen including the commemorative dividend of 30 yen.

Dividend trend



Unit: Yen


Terminology

Term	Definition
PWB	Printed Wiring Board
SR	"Solder resist ink" or "Solder mask"
PKG	Semiconductor packages
DF	Dry Film

Product Classification

Group	Category		Туре	Remarks		
PWB insulating materials	Rigid	High end	Liquid			
	rugia	Regular	Liquid / DF	•SR materials for insulation and surface protection use		
	PKG		Liquid / DF	•Electronics materials		
	FPC (Flexible printed circuit board)		Liquid / DF			
	Build-up		Liquid / DF	Build-up materials for interlayer insulation and hole plugging use		
Other related products	Others		Others I		Liquid	 Marking, etching, plating materials Flux, conductive silver paste, solvent etc.


Net Sales by product category



Unit: JPY Million

Net Sales by sales area

Unit: JPY Million



Taiyo Ink Vietnam – Plant to start operations

- Entering the Vietnamese market anticipating future market expansion
- Shortening delivery time to our customers in the ASEAN region

Plant Overview

Name

TAIYO INK VIETNAM CO., LTD.

Location

Lot 37-2, Quang Minh Industrial Park, Quang Minh Town, Me Linh District, Hanoi

Representative

General Director Koji Kurihara

Product

Solder Resist Ink (Rigid - High end)

Start of operations

July 2021 (Planned)



Onstatic INK(OTC) moved plant from Shenzhen to JiangXi province

- Improve access to customers in the Central China region
- Increase production capacity in China

Compliant with Chinese environmental regulations in the long term

Name Onstatic New Material(Jiang Xi)Co.,Ltd. Location Cheng Dong Industrial Zone, FenYi county XinYu city JiangXi China Representative Chairman of the Board Takayuki Morita Product Solder resist Ink (Rigid – Regular)

July 2021 (Planned)



operations

Taiwan Taiyo Ink - Start of operation of new office building & plant

- Renovated due to the aging of the existing building (at the same site)
- Design and equipment that can flexibly respond to fluctuations in production volume

Overview of new office building & plant

Name

TAIWAN TAIYO INK CO., LTD.

Location

No.7, Datong 2nd Rd., Guanyin Industry Park, Guanyin Dist., Taoyuan

Representative

Chief-Executive Officer Hitoshi Saito

Product

Solder resist Ink (Rigid – High end, Rigid - Regular)

Start of operations

July 2021 (Planned)



Medical and Pharmaceuticals Business

Medical and Pharmaceuticals Business

Terminology

Term	Definition
LLP	A drug for which the patent or re-examination period has expired, enabling the sale of generic drugs(Long Listed Product)
CDMO	Organizations that are contracted to manufacture drugs and to develop drug formulation (Contract Development Manufacturing Organization)
GMP	Standards for manufacturing control and quality of pharmaceuticals and quasi-drugs (Good Manufacturing Practice)

Taiyo Pharmatech - acquisition of a distribution center

- Taiyo Pharmatech plans to acquire a distribution center adjacent to its plant from Daiichi Sankyo Company, Limited and Daiichi Sankyo Propharma Co., Ltd. on June 1st, 2021
- Enhanced product storage and shipping functions for contract manufacturing of pharmaceutical products to various customers
- Scheduled to be used as a new space for manufacturing pharmaceuticals

Distribution center (Adjacent to Taiyo Pharmatech, Takatsuki City, Osaka Prefecture)





Site Area : **13,281m**

Asset Overview: Land, multi-level

automated warehouse, flat warehouse and other

assets



Selected as a naming rights partner for Takatsuki City's facilities

Taiyo Pharmatech is selected as a naming rights partner for the facility "Small Hall" in Takatsuki Castle Park Arts and Culture Theater

Facility name: Taiyo Pharmatech Hall (planned)



Period: 10 years from the opening date

Scheduled opening date: March 2023

Application amount: 10 Million yen (in total)




Photo of the facility



ESG

Environment: Renewable energy initiatives



Environment: Renewable energy initiatives

- Achieve 100% renewable energy by floating solar power generation
- Estimated annual power generation 22GWh (covers 100% or more of domestic electricity consumption for the electronics materials business)
- Participating in Apple's 2020 Clean Energy Program



Governance: Board of Directors

Half of the directors are independent outside directors, and the ratio of women exceeds 30%. This has led to adding value to discussions at the Board of Directors meetings and also improving governance



President and CEO Eiji Sato



Director Eiji Takahara



Director Hitoshi Saito



Director Toshifumi Tamaki



Director (Outside) Masayuki Hizume



Director (Outside) Keiko Tsuchiya



Director (Outside) Asako Aoyama



Director (Outside) Yumiko Kamada

Earnings forecast

Forecast for the fiscal year ending March 2022

Consolidated full-year earnings forecast Unit: JPY Million

	FY2021 Full year	FY2022 Full year		
	Result	Forecast	Change	%
Net sales	80,991	86,500	5,509	7%
Operating Income	13,943	12,100	-1,843	-13%
Ordinary Income	13,819	12,000	-1,819	-13%
Net Income	9,529	8,300	-1,229	-13%
Exchange rate of JPY/USD	106.2	108	1.8	
EBITDA	21,420	19,900	-1,520	-7%
Operating Income Margin	17%	14%		
EBITDA Margin	26%	23%		

Consolidated Earnings Forecast by Segment for the Fiscal Year Ending March 2022

Earnings forecast by segment

	FY2021 Electronics	FY2022 Electronics			FY2021 Medical and	FY2022 Medical and		
	Materials Full year Result	Materials Full year Forecast	Change	%	pharmaceuticals Full year Result	Pharmaceuticals Full year Forecast	Change	%
Net Sales	53,096	58,400	5,304	10%	24,553	23,900	-653	-3%
Operating Income	11,208	12,300	1,092	10%	3,837	1,400	-2,437	-64%
Exchange rate of JPY/USD	106.2	108	1.8		106.2	108	1.8	
EBITDA	12,970	14,300	1,330	10%	8,668	6,000	-2,668	-31%
Operating Income Margin	21%	21%			16%	6%		
EBITDA Margin	24%	24%			35%	25%		

Unit: JPY Million

Trend of consolidated business performance


Consolidated Business Performance Trends

Unit: JPY Million



Capital investment and depreciation

Yearly trends: Capital Investment/Depreciation W Unit: JPY Million



*Capital investment: Investment in property, plant and equipment and software Depreciation: Depreciation of property, plant and equipment and software



